Associations Of Betatrophin Levels With Fasting Blood Glucose In Obese Females

Pradika Gita Baskara, Lilik Herawati, Purwo Sri Rejeki*
Universitas Airlangga, Surabaya, East Java, Indonesia
purwo-s-r@fk.unair.ac.id; purwo_faal@yahoo.com

ABSTRACT
The prevalence rate of obesity is very concerning both in developed and developing countries and poses a very serious threat to health in the world. Betatrophine is a hormone secreted by liver and collected by homeostasis. Betatrophin levels increase higher in obese people and type 2 (two) diabetes mellitus sufferers. This study aims to analyze the correlation between the levels of betatrophin and fasting blood glucose (FBG) in obese females. This study used a cross sectional study method of 26 obese female aged 18-23 years old, body mass index (BMI) 25-35 kg/m² and body fat percentage (PBF) above 30%. Betatrophin levels were measured by ELISA method, while FBG measurements used ACCU-CHEK® Performance. The data analysis techniques used the Pearson Correlation test with the Statistical Package for Social Sciences (SPSS). The results obtained the average of betatrophin level (165.707 ± 96.124) pg / mL and the average of FBG (90.576 ± 7.094) g / dL (p = 0.021). Based on the results of the study it can be concluded that there is a correlation between levels of betatrophin and FBG in obese adolescent girls with a negative correlation direction.

Keywords: Levels Betatrophin, Fasting Blood Glucose, Obese Females.
INTRODUCTION

Obesity is a condition where there is excessive accumulation of body fat (Hruby and Hu, 2015). The prevalence rate of obesity is very concerning both in developed and developing countries and poses a very serious threat to health in the world (Marie et al., 2014; Peterson et al., 2014). According to the World Health Organization (WHO) (2019), the prevalence of obesity at the age of 18 years has increased from 1980 by 13% to 24% in 2008 and 26% in 2016. In Indonesia, based on the results of the Basic Health Research (Riskesdas) in 2018 showed that the prevalence of obesity at the age (over 18 years) reached 21.8%, the number was higher than in 2013 (14.8%) and 2007 (10.5%) (Riskesdas, 2018). However, it did not receive any special attention. Obesity is known to have the potential to increase the risk of disability and various non-communicable chronic diseases (Kibria, 2019) at risk of death including premature death (Rosella et al., 2019). It is because the obesity increases the risk of cardiovascular disease, cancer (Hruby and Hu, 2015), discipline, anemia, sleep apnea syndrome, non-alcoholic fatty liver disease (NAFLD), musculoskeletal disorders (Fruh, 2017), premature death and disability (OECD, 2017). In addition, obesity also increases the risk of developing metabolic syndrome diseases such as type 2 diabetes mellitus, insulin resistance (Boden, 2011), hypertension (Midha et al., 2014) and hypercholesterolemia (Felix-Redondon et al., 2013). Obesity is often associated with increased levels of betatrophin (Abu-Farha et al., 2016; Crujeiras et al., 2016). Betatrophin is a hormone secreted by liver and adipose tissue (Peng et al., 2013). However, the hormone betatrophin is more secreted by liver in human body (Ren et al., 2012). Betatrophin can stimulate pancreas to produce insulin (Peng et al., 2013). In addition to obese patients, increased levels of betatrophin are also found in type 1 diabetes mellitus patients (Yamada et al., 2014), type 2 diabetes mellitus (Espes et al., 2014; Xie et al., 2015), gestational diabetes mellitus (Ebert et al., 2015) al., 2015; Trebotic et al., 2015 and polycystic ovarian syndrome (PCOS) (Qu et al., 2017). Increased levels of excessive betatrophin in obese people can inhibit the performance of the enzyme lipoprotein lipase (LPL), thus making it difficult to convert fat into energy (Xie et al., 2015). Increased levels of betatrophin are also influenced by age, sex, HbA1c, fasting blood glucose, systolic pressure and triglycerides (Maurer et al., 2017). Some of the research that has been done has given mixed results such as the research that conducted by Battal et al. (2018) concluded that there is no correlation between betatrophin levels and blood glucose in obese male and female. Likewise, the study of Guo et al. (2015) found similar results that there is no correlation between serum betatrophin levels and fasting blood glucose in obese elderly and type 2 diabetes mellitus elderly patient. However, the research that conducted by Barja-Fernandez et al. (2015) found the different results that there is a correlation between levels of betatrophin and blood glucose in obese women. So far, the correlation between levels of betatrophin and fasting blood glucose in obese adolescent girls is still unclear, however the researchers take this intervention as something for further research. Based on the background of the problem above, the purpose of this study is to analyze the correlation between betatrophin levels and fasting blood glucose in obese adolescent girls.

METHODS

This study used a cross-sectional study method of 26 obese female aged 18-23 years old, body mass index (BMI) 25-35 kg/m², body fat percentage (PBF) above 30%, with
normal blood pressure and resting heart normal rate (RHR). All of these research procedures were approved by the Health Research Ethics Commission of the Faculty of Medicine, Airlangga University, Surabaya number 309 / EC / KEPK / FKUA / 2019. Collecting blood was from cubital veins with 4ml. The blood was centrifuged for 15 minutes at 3000 rpm. The serum was separated and stored at -80 ° C for analysis of betatrophin levels in the following day. Collecting blood was done at 7-9 a.m. Betatrophin levels measured by using ELISA kit (Cat No. E11644h; EIAab Science Co., Wuhan) with a unit of concentration of pg / mL. FBG measurements using ACCU-CHEK (ACCU-CHEK® Performa, Mannheim, Germany) with g / dL concentration units. The subject used the consecutive sampling techniques. Statistical analysis used statistical software packages for social science (SPSS). The normality test used the Shapiro-Wilk test. Data that normally distributed were tested using Pearson correlation with a significant level (P <0.05). All data were displayed with mean ± SD.

RESULTS
The results of descriptive analysis of the research subjects characteristics can be seen in table 1 below.

Table 1. Characteristics of Research Subjects

<table>
<thead>
<tr>
<th>Variabel</th>
<th>n</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>26</td>
<td>20.846</td>
<td>1.120</td>
</tr>
<tr>
<td>Height (m)</td>
<td>26</td>
<td>1.577</td>
<td>0.050</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>26</td>
<td>72.200</td>
<td>7.346</td>
</tr>
<tr>
<td>IMT (kg/m²)</td>
<td>26</td>
<td>28.942</td>
<td>1.682</td>
</tr>
<tr>
<td>Systole Blood Pressure (mmHg)</td>
<td>26</td>
<td>113.076</td>
<td>4.706</td>
</tr>
<tr>
<td>Diastole Blood Pressure (mmHg)</td>
<td>26</td>
<td>75.769</td>
<td>5.038</td>
</tr>
<tr>
<td>RHR (bpm)</td>
<td>26</td>
<td>77.730</td>
<td>11.643</td>
</tr>
<tr>
<td>PBF (%)</td>
<td>26</td>
<td>43.619</td>
<td>4.123</td>
</tr>
</tbody>
</table>

Table 1 shows that the average age of subjects was 20,846 years old with height 1,577m, body weight 72,200 kg, BMI 28,942 kg/m2, blood pressure systole and diastole 113,076/75,769 mmHg, RHR 77,730 bpm and average PBF 43,619%. The results of the correlation analysis between levels of betatrophin and FBG can be seen in table 2.

Table 2 Correlation Of Betatrophin Levels and FBG

<table>
<thead>
<tr>
<th>Variabel</th>
<th>n</th>
<th>Mean±SD</th>
<th>Pearson r</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betatrophin (pg/mL)</td>
<td>26</td>
<td>165.707±96.124</td>
<td>-0.401</td>
<td>0.021*</td>
</tr>
<tr>
<td>FBG (g/dL)</td>
<td>26</td>
<td>90.576±7.094</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Based on table 1 Pearson correlation test results showed that there is a correlation between levels of betatrophin and FBG with a negative correlation direction (p = 0.021).

DISCUSSION
Based on the results of the study showed that there is a correlation between levels of betatrophin and FBG with a negative correlation direction (p = 0.021) in obese adolescent
This result is confirmed by previous research conducted by Amri et al. (2019) that showed there is a negative correlation between betatrophin and FBG. In addition, the previous studies are almost the same with Maurer et al. (2017) showed that there is a correlation between levels of betatrophin and FBG with p < 0.001. Based on the average value of betatrophin showed a high mean while FBG showed a low average, so there is a negative correlation. This is probably due to betatrophin affecting FBG through the mechanism of betatrophin causing beta-pancreatic cell regeneration so that insulin resistance experienced by obese people can be overcome in the disruption of the insulin signaling pathway which causes a decrease in FBG, so the higher betatrophin, the lower FBG can be. Betatrophin hormone that mainly produced in liver is a key stimulator of beta cell mass expansion in response to obesity and a state of insulin resistance. The fact shows that a 17 fold-increase in beta cell proliferation when the hormones are overexpressed (Espes et al., 2014). Obesity occurs excessive fat accumulation in the body. The fat tissue is an active endocrine tissue that can release adipose cytokines. This adipose cytokine has a proinflammatory effect and can also disrupt the insulin signaling pathway which ends in a state of insulin resistance. Insulin resistance that occurred can cause an increase in blood glucose levels (Clare et al., 2007). The results of previous study by Polli et al. (2016) added that in a state of obesity there is a decrease in adiponectin and an increase in free fatty acids that are opposite to the effects of insulin, causing a decrease in insulin sensitivity or insulin resistance. Fatty acids and some other metabolic activates protein kinase and break the insulin signaling by increasing serine phosphorylation which is inhibitory of the insulin receptor substrate (IRS), thus causing insulin resistance. In insulin resistance, an increasing of glucose production and a decreasing of glucose used the results blood glucose levels increasing. However, this study shows that betatrophin is increased so that the insulin signaling pathway is not disrupted which results in a decrease of FGB. The mechanism is preceded by the increase of betatrophin which causes beta-pancreatic cell regeneration, so that insulin resistance experienced by obese people can be overcome with the results in the disruption of the insulin signaling pathway (Amri et al., 2019). Signaling insulin that is not interrupted or can be said to be smooth will activate protein kinase B (PKB) / AKT which has an impact on increasing glucose transporter type-4 (GLUT-4) translocation. As a result of increased GLUT-4 translocation, it will cause an increase in blood glucose uptake (Khorami et al., 2015). Increased uptake of blood glucose will affect FBG levels, namely a decrease in FBG levels (Odera et al., 1982; Blodgett et al., 2007). Beside that, the negative correlation betatrophin and FBG in obesity is also influenced by several factors.

FBG levels in each individual with obesity can be influenced by several other factors such as diet, physical activity, genetic factors, type of research used (in cross sectional studies that are taking risk and effect data at the same time, data-used in research ( primary or secondary), the measurement of the respondent's degree of obesity using anthropometric measurement methods in form of what is used, for example body mass index (Putri et al., 2015). In this study, we used a cross sectional study method and the measurement of the degree of obesity of respondents using the body mass index ( BMI) 25-35 kg / m2. In addition, regarding diet and physical activity in this study were also controlled, so that all subjects received the same treatment with same diet and physical activity, then related to the data used in the study, it is using secondary data from the laboratory for levels of betatrophin cells For ELISA kit (Cat No. E11644h; EIAab Science Co., Wuhan) with pg / mL concentration units, and FBG examination is carried out directly using ACCU-CHEK.
(ACCU-CHEK® Performa, Mannheim, Germany) with g/dL concentration units, through the betatrophin and FBG examination methods performed, also to minimize the risk of bias so that the obtained-data is accurate. Therefore, in this study the influencing factors can be minimized so that it does not affect FGB. However, the decrease in pure FGB was influenced by an increase in betatrophin. This is indicated by the results which says that there is a negative correlation between betatrophin and FBG.

CONCLUSION

Based on the results of the study it can be concluded that there is a correlation between levels of betatrophin and FBG in obese adolescent girls with a negative correlation direction. Based on the results of the study, it is recommended to do further research by using more subjects to strengthen the findings in this study. In addition, it is also advisable to use subjects who have a history of diseases such as type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus, polycystic ovarian syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD).

REFERENCES


Blodgegett et al. 2007. Structural Basis of Glut 1 inhibitory by cytoplasmic ATP. J Gen Physiol, 130(2).


